Our lead program candidate, STAR-0215, is a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting, safe, and effective attack prevention for HAE, with potential for dosing once every three months or less frequently. We shared positive preliminary results from our Phase 1a clinical trial in healthy subjects in 2022, and initiated the proof-of-concept ALPHA-STAR trial in people living with HAE in early 2023. Initial proof-of-concept results in HAE patients from single and multiple dose cohorts are expected in mid-2024.

Astria TX on Facebook Astria TX on Twitter Astria TX on LinkedIn Astria TX on Instagram